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Abstract: Oxidative stress has been implicated in the progression of a number of 
neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease and 
amyotrophic lateral sclerosis. We carried out an in-depth study of cognitive impairment 
and its relationships with oxidative stress markers such as ferric-reducing ability of plasma 
(FRAP), plasma malondialdehyde and total antioxidative capacity (TAC), as well as cholesterol 
parameters, in two subsets of subjects, AD patients (n = 59) and a control group of neurologi-
cally normal subjects (n = 29), attending the University Hospital Salvador in Santiago, Chile. 
Cognitive impairment was assessed by a set of neuropsychological tests (Mini-Mental State 
Examination, Boston Naming Test, Ideomotor Praxia by imitation, Semantic Verbal Fluency 
of animals or words with initial A, Test of Memory Alteration, Frontal Assessment Battery), 
while the levels of those oxidative stress markers and cholesterol metabolism parameters were 
determined according with standard bioassays in fresh plasma samples of the two subgroups 
of patients. No signiﬁ  cant differences were observed when the cholesterol parameters (low-, 
high-density lipoprotein, total cholesterol) of the AD group were compared with normal con-
trols. Interestingly, a correlation was evidenced when the levels of cognitive impairment were 
analyzed with respect to the plasma antioxidant capacity (AOC) of patients. In this context, the 
subset of subjects exhibiting cognitive impairment were divided into two subgroups according 
with their Global Dementia Scale performance: a subgroup with mild AD and a subgroup with 
moderate to severe AD. Signiﬁ  cant differences in AOC were found between subgroups. The 
different correlations between cognitive impairment of subgroups of subjects with the oxidative 
stress proﬁ  le are discussed in the context of AD pathogenesis.
Keywords: oxidative stress, molecular biomarkers, cholesterol parameters, cognitive 
impairment, Alzheimer’s patients
Introduction
Alzheimer’s disease (AD) is the most common cause of dementia nowadays. This 
disease is characterized by the formation of protein aggregates in the human brain, 
namely paired helical ﬁ  laments composed of hyperphosphorylated tau and senile 
plaques of Aβ (Maccioni et al 2001). The pathogenesis of AD and other neurodegen-
erative disorders has been related with oxidative stress, which might be responsible for 
the resulting dysfunction and death of neuronal cells. Oxidative stress is the result of 
the unregulated production of reactive oxygen (ROS) or nitrogenated species, which 
alters the structure of proteins, lipids and nucleic acids (Perry et al 2000; Barnham et al 
2004). These investigations have suggested several hypotheses on the mechanisms of 
pathogenesis potentially implicated in AD as related with oxidative damage. Studies 
have also pointed to relationships between progression of dementia and neurodegen-
erative disorders with the increase in oxidative stress biomarkers (Kikuchi et al 2002; 
Nunomura et al 2007).Neuropsychiatric Disease and Treatment 2008:4(4) 716
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Moreover, evidence exists that cholesterol is linked to 
the development of AD (Rojo et al 2006). Hypercholester-
olemia is an early risk factor for the development of amyloid 
pathology, and longitudinal, population-based studies dem-
onstrated that cholesterol is associated with AD in the later 
lifespan (Kivipelto et al 2001). On the other hand, ApoE 
participates in the transport of cholesterol and other lipids 
in the blood stream and in the cerebrospinal ﬂ  uid (CSF). 
This protein is expressed by three major alleles: ε2, ε3, and 
ε4, being the homozygozity for Apoε4, is the most relevant 
risk factor for AD (Corder et al 1993; Lavados et al 2005). 
However, its mode of action is still unknown (Goedert and 
Spillantini 2006). The levels of peroxidation in the brains of 
AD patients depended on the ApoE genotype, and is higher 
when Apoε4 allele is present, while the level of peroxida-
tion was inversely proportional to the concentration of ApoE 
(Rammassamy et al 1998). This lipid-transport protein is a 
target for the attack of free radicals, and a correlation exists 
between ApoE peroxidation and AD (Leininger-Muller 
et al 1998). Prior studies with patients had conﬁ  rmed that 
oxidative stress is clearly associated with cognitive decline 
(Berr et al 2000), and an oxidative imbalance in AD patients 
has been proven with different oxidative stress biomarkers 
(Pulido et al 2005; Guidi et al 2006; Zafrilla et al 2006).
In this article, we analyze the oxidative stress status and 
some of the cholesterol metabolism parameters from a group 
of AD patients with different stages of dementia, as compared 
with neurologically normal controls. Moreover, we have also 
attempted to correlate cognitive impairment with changes in 
cholesterol homeostasis.
Materials and methods
Subjects
Eighty-eight subjects in total were included in this study. All 
the recruited participants were more than 60 years-old and 
recruited from the Metropolitan area population of Santiago, 
Chile, genetically composed by around 40% Amerindians 
and 60% Caucasians. The AD patients subset included ﬁ  fty-
nine subjects (mean age 76.4 years, SD 6.1, 32 women and 
27 men) diagnosed with probable Alzheimer-type dementia 
according to NINCDS/ADRDA criteria (McKhann et al 
1984). This subset was compared with twenty-nine control 
subjects (mean age 70.7 years, SD 6.9, 20 women and 9 men). 
The subjects in the control subset were recruited from among 
elderly relatives with the indicated ages and gender distribu-
tions. All patients and control subjects were incorporated 
into the study after informed consent. Only subjects giving 
informed consent for themselves or from caregivers, and 
able to be evaluated neuropsychologically were recruited, 
thus concentrating the population in the study in 88 subjects. 
They did not exhibit psychiatric and neurological clinical 
antecedents. Moreover, none of the participants had any other 
major medical illness or were taking any medication known 
to affect oxidative stress markers or the cholesterol param-
eters. Moreover, caution was taken that individuals recruited 
in the study were not taking any supplement of vitamin E 
or C, nor extracts with high content of polyphenols (Vitis 
vinifera, Ginkgo biloba, Camellia sinensis). The education 
level of the entire population was also analyzed. For evalua-
tion of cholesterol and oxidative markers parameters, venous 
blood samples were obtained from each subject under study. 
Subjects were under fasting condition early in the morning, 
and determinations were carried our in the separated plasma 
samples. All the experimental protocols were approved by 
the Committee on Ethical Issues of the Faculty of Medicine, 
University of Chile, and all subjects provided informed 
consent prior to the initiation of the study. In the cases of 
demented subjects, the informed consent for participation in 
the study was obtained from their caregivers.
Neuropsychological battery of tests
Once the subjects were included in the AD or control 
group, they were subjected after informed consent of their 
caregivers, a neuropsychological battery of tests. The 
neuropsychological evaluation consisted of the neuropsy-
chological battery that includes Mini Mental State Examina-
tion (MMSE), Grober and Buschke, Global Dementia Scale 
(GDS) (Reisberg et al 1998), Ideomotor Praxia by imitation 
(PRAXIAS), Boston Naming Test (BNT) of 12 images, 
Frontal Assesment Battery (FAB), and Semantic Verbal 
Fluency of animals or words with initial A (FLU Animals 
and FLU A). Thus the 88 subjects in the study were properly 
evaluated and included in all measurements.
Measurement of cholesterol parameters
The total plasma cholesterol levels were determined using the 
cholesterol assay (Abbott Diagnostics, Huechuraba, Chile) 
according to the manufacturer’s instructions. The low-density 
lipoprotein (LDL) cholesterol in human plasma was measured 
using a MULTIGENT Direct LDL assay (Abbott Diagnostics). 
In the same way, the quantitation of high-density lipoprotein 
(HDL) cholesterol in human plasma was employed the Ultra 
HDL assay (Abbott Diagnosis). The VLDL cholesterol was 
calculated as the difference between total cholesterol and both 
HDL and LDL. The index total cholesterol/HDL was calculated 
with the data obtained of the experimental measurements.Neuropsychiatric Disease and Treatment 2008:4(4) 717
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FRAP assay
The ferric-reducing ability of plasma (FRAP assay) was 
adapted from the original protocol (Benzie and Strain 1996) 
with minor modiﬁ  cations introduced by Pulido and colleagues 
(2000). This method is based on a single electron transfer 
reaction between an oxidant and the antioxidants, ie, plasma 
antioxidants are oxidized by the oxidant Fe(III). Thus, a single 
electron is transferred from the antioxidant molecule to the 
oxidant. Brieﬂ  y, 900 μL of FRAP reagent, prepared freshly 
was mixed with 90 μL of distilled water and 30 μL of plasma 
sample. Water was used for the reagent blank. The FRAP 
reagent contained 2.5 mL of a 10 mmol/L TPTZ solution in 
40 mmol/L HCl plus 2.5 mL of 20 mmol/L FeCl3*6H2O and 
25 mL of 0.1 mol/L acetate buffer, pH 3.6. The change of 
absorbance of the Fe-(TPTZ)2(III) complex (FRAP reagent), 
due to the action of an antioxidant in the plasma, was mea-
sured at 593 nm by a spectrophotometer after twenty minutes 
of reaction-stabilization period. The absorbance value is used 
as the measurement for the reducing capability of the antioxi-
dant. Aqueous solutions of known Fe(II) concentrations in 
the range of 100–2000 μmol/L (FeSO4*7H2O) were used for 
calibration. All measurements were performed in triplicates. 
FRAP analysis is widely used in the evaluation of antioxidant 
capacity in biological ﬂ  uids including plasma, since it is a 
simple, reliable, and fast technique. FRAP measurements were 
complemented with TAC-crocin that allows determinations of 
the protecting capacity of blood plasma against peroxidative 
agents, as indicated below.
Serum lipid peroxide measurement
Levels of lipid peroxidation were measured as the formation 
of a thiobarbituric acid (TBA) adduct of malondialdehyde 
(MDA). The serum lipid peroxide measurement was used 
with minor modiﬁ  cations in the original protocol (Satoh 
1978). The standard procedure was established as follows: To 
0.25 ml of plasma sample, 1.25 ml of 1.23 M trichloroacetic 
acid (TCA) were added and the mixture was left to react for 
10 min at room temperature. After centrifugation at 1500g 
for 10 min, the supernatant was decanted and 1.25 mL of 
sulfuric acid 5 mM was aggregated to the precipitate, and 
then ultrasonicated three times for 15 sec immersion in ice-
cool water. Next, we added 1.5 mL of TBA 16 mM, and the 
coupling reaction of the lipid peroxide with TBA was carried 
out by heating in a boiling water bath for 60 min. After cool-
ing in cold water, the resulting chromogen was extracted 
with 1.0 ml of n-butanol by vigorous shaking in vortex. The 
organic phase was separated by centrifugation at 1500 g for 
5 min. Then, the optical density was determined at 532 nm. 
The standard curves were performed with MDA solutions 
(0.075–2.25 μmol/L), and 5 mM sulfuric acid was used as a 
blank. All measurements were performed by triplicate.
Total antioxidant capacity by the crocin 
bleaching assay
Crocin bleaching assay was used with minor modiﬁ  cations 
to the original protocols (Tubaro et al 1996; Malliaraki et al 
2003). Brieﬂ  y, crocin was extracted and puriﬁ  ed from saffron 
according with the method of Ordoudi and Tsimidou (2006). 
A stock solution of crocin was prepared in methanol and was 
diluted with 0.1 mol L-1 phosphate buffer, pH 7.0 in order to 
obtain a 1.35 × 10−5 mol L-1 crocin solution (the absorption 
coefﬁ  cient of crocin at 443 nm is 1.33 × 105 mol-1 cm-1). 
As initiator, a stock solution of AAPH (250 mmol L-1) was 
prepared in PBS 10 mmol L-1 pH 7.0. The assay was per-
formed in the cuvettes adding the reactants in the following 
order: 20 μL of plasma sample or standard, 80 μL of AAPH 
(250 mmol L-1) and ﬁ  nally 1000 μL of crocin solution. 
Bleaching rate of crocin at 443 nm was monitored at 40 °C 
during 25 minutes using a V-500 spectrophotometer (Jasco, 
Easton, MD, USA). The blank reference cuvette contained 
only phosphate buffer solution. Antioxidant capacity was 
calculated using similar expressions adapted from ORAC 
methodology (Cao et al 1999; Ou et al 2001). The corrected 
area under the relative absorbance curve (AUC) of each 
sample was compared with those obtained from the standard 
curve made from Trolox (3.5–60 μmol L-1), and results 
were expressed as μmol of Trolox equivalent per milliliter 
of plasma (TEAC). These TEAC values refer to the net 
protection (AUC) of crocin in presence of an antioxidant. 
All measurements were performed in triplicates. Thus, in 
all the studies corrected values of TAC were obtained after 
substracting circularing antioxidant agents such as uric acid, 
bilirubin, and lipoproteins (Kampa et al 2002).
Statistical analysis
Statistical analysis was performed with GraphPad Prism4 pro-
gram (GraphPad Software, La Jolla, CA, USA). Comparisons 
were made by student t-test for normally distributed variables. 
One-way ANOVA and Bonferroni’s Multiple Comparison 
Test were used to test differences in mean values. All contrasts 
were made considering alpha lower than 5% to be an error. 
Correlations were assessed by Pearson’s method.
Results
Demographic and neuropsychological data among the two 
groups in the study are given in Table 1. No signiﬁ  cant Neuropsychiatric Disease and Treatment 2008:4(4) 718
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differences were found in the educational levels between 
the subsets of subjects (p  0.05). A signiﬁ  cant difference 
(p = 0.0002) in the mean ages of AD patients as compared 
with ages of the control group was obtained in the recruited 
population. AD patients were from moderately to signiﬁ  -
cantly impaired in their cognitive performance, on the basis of 
all neuropsychological tests relative to control performance. 
As expected, the means of AD group were smaller than the 
control group in all the tests.
Mean values of cholesterol parameters and SD are 
reported in Table 2. No signiﬁ  cant differences were found 
between the two AD and control subsets in the study. This 
data also agreed with other authors (Corzo et al 2007).
The oxidative stress biomarkers analyzed in this article 
are summarized in Table 3. In all the assays applied, no 
statistical differences were observed between the AD subset 
and the control subjects. However, when subjects exhibiting 
cognitive impairment were divided into subgroups according 
with their GDS performance score, signiﬁ  cant differences 
in FRAP were found between the controls and the moderate 
and severe AD subgroups, and between mild and moderate/
severe AD (Figure 1).
However, differences between AD and controls were not 
observed for the MDA levels and TAC-crocin when the sub-
groups were classiﬁ  ed by GDS scores. Then, we tried to ﬁ  nd 
correlations between the cognitive performance and oxidative 
stress biomarkers. Antioxidant capacity values measured 
by FRAP methods were positively correlated with MMSE 
(r = 0.443, P  0.01) and PRAXIAS (r = 0.301, P < 0.05) 
(Figure 2). We could not ﬁ  nd another correlation between 
oxidative stress status and the cognitive impairment.
Finally, we investigated the correlations between 
cholesterol parameters and the results of the neuropsy-
chological tests. In this case, a negative correlations 
between total cholesterol (r = −0.298, P  0.05) and VLDL 
(r = −0.382, P  0.01) versus GDS was found (Figure 3). 
Instead, a positive correlation (r = 0.464, P  0.01) was 
found between the cholesterol/HDL index and the BNT or 
semantic memory (Figure 4). No correlations were found 
with the other cholesterol metabolism parameters like HDL, 
LDL, or triglycerides.
Discussion
We did not ﬁ  nd statistically signiﬁ  cant differences in deter-
minations of plasma FRAP and TAC-crocin in AD subjects 
as compared with controls. Similar results are reported in 
the literature concerning plasma TAC measurement in AD 
patients (Sinclair et al 1998; Feillet-Coudray et al 1999; 
Pulido et al 2005), however other studies have shown a lower 
plasma TAC in AD patients (Reppetto et al 1999; Serra et al 
2001; Guidi et al 2006).
However, when the subset of cognitively impaired sub-
jects were stratiﬁ  ed by their GDS status, signiﬁ  cant differ-
ences were found in the FRAP average values between the 
subgroups of patients. In our study, those patients with mod-
erate/severe AD displayed the lowest anti-oxidant capacity 
Table 1 Demographic data and cognitive performance differences between groups in the study
 Control  group  AD  group
  n  Mean  value SD n  Mean  Value SD p
Age 29  70.7  6.9  59  76.4  6.1  0.05
Education 29  8.6  3.0  59  7.7  4.5  0.05
MMSE 29  25.0  3.1  53  14.1* 6.0  0.05
PRAXIAS 29  4.8  0.7  53  3.4*  1.6  0.05
FLU ANIMAL  29  14.4  4.2  48  7.4*  3.5  0.05
FLU A  28  9.4  3.7  45  5.0*  3.2  0.05
BNT 28  10.0 2.6  42  4.7* 4.0  0.05
FAB 27  13.8  3.0  43  9.0*  3.4  0.05
TAM 29  39.7 5.6  37  16.9*  8.2  0.05
Abbreviations: AD, Alzheimer’s disease; BNT, Boston Naming Test; FAB, Frontal Assessment Battery; FLU A, semantic verbal ﬂ  uency of words with initial A; FLU ANIMAL, 
Semantic Verbal Fluency of animals with initial A; MMSE, Mini Mental State Examination; PRAXIAS, Ideomotor Praxia by imitation; SD, standard deviation; TAM, Test 
of Metalinguistic Ability.
Table 2 Comparison of the cholesterol parameters (mg/dL) of AD 
subjects and neurologically normal controls
 Control  (n  = 29)  AD (n = 55)
  Mean Value  SD  Mean Value  SD  p value
Total-cholesterol 200  42  202  39  > 0.05
Tryglicerides 147  58  132  55  > 0.05
HDL-cholesterol 54  13  52  11  > 0.05
LDL-cholesterol 122  34  127  34  > 0.05
VLDL-cholesterol 23  7  23  8.0  > 0.05
cholest/HDL index  3.8  0.7  4.0  0.9  > 0.05
Abbreviations: AD, Alzheimer’s disease; HDL, high-density lipoprotein; LDL, 
low-density lipoprotein; SD, standard deviationNeuropsychiatric Disease and Treatment 2008:4(4) 719
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by FRAP assay. This result is consistent with Zafrilla and 
colleagues (2006) that characterized the total antioxidant 
plasmatic status of the AD patients. Both the light-moderate 
AD subjects and patients with an advanced phase of AD 
exhibited lower FRAP values than in the controls. This is 
a novel and interesting observation. Previous reports that 
investigated this speciﬁ  c aspects, did not ﬁ  nd this type of 
relationship in the plasma of AD patients (Ceballos-Picot et al 
1996). Interestingly, Pulido and colleagues (2005) discovered 
a lower antioxidant capacity of AD plasma samples by FRAP 
method only in subjects with APOE genotype ε4/ε4, which 
is the group with the highest incidence of AD. We have to 
point out that FRAP should be analyzed in a global context 
together with other biochemical parameters, and considering 
some nutritional conditions of subjects.
On the other hand, we observed no modiﬁ  cation in plasma 
malondialdehyde (MDA) levels when AD patients were com-
pared with control subjects. This observation is different from 
previous publications that reported signiﬁ  cant differences 
in MDA levels of erytrocytes of AD patients as compared 
with the controls (Bermejo et al 1997). In other studies, the 
ex - vivo susceptibility to lipid peroxidation was higher in 
mild and moderate AD with respect to controls, but not in 
severe AD patients (Galbusera et al 2004). Peroxidation was 
higher in patients in the advanced stage of the disease than 
in the control group. However, no signiﬁ  cant differences 
were observed between the different stages of the disease 
(Zafrilla et al 2006).
We explored the association of plasma oxidative compo-
nents to cognitive impairment in mild and severe conditions 
Table 3 FRAP, MDA levels, and TAC-crocin mean values and SD in both AD and control groups
 Control  AD
  n  Mean value  SD  n  Mean value  SD  P value
FRAP (μM eq. Fe2+) 29  1,215  317  59  1,118  253   0.05
MDA levels (μmol/L) 29  0.67  0.48  59  0.57  0.34   0.05
TAC-crocin (μmol/L Trolox/mL plasma)  14  13.1  6.6  31  11.2  4.8   0.05
Abbreviations: AD, Alzheimer’s disease; FRAP, ferric-reducing ability of plasma; MDA, malondialdehyde; SD, standard deviation; TAC, total antioxidative capacity.
FRAP values in  the AD group divided
by GSP score and K group
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Figure 1 Ferric reducing ability of plasma (eq. Fe(II) μM) of patients with Alzheimer’s 
disease at different stages of the disease, as evaluated by GDS. Other details in Methods. 
The number of subjects in every group (n) was: n = 23 in the mild AD (GDS = 3–4); n = 24 
in the moderate AD (GDS 5), and n = 12 for severe AD; n = 29 for the control group.
Note: * Signiﬁ  cant differences (p  0.05) between control subgroup (or mild AD) vs 
moderate or severe AD. One-way ANOVA and Bonferroni´s comparison test wre used 
to assess differences in mean values.
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Figure 2 (A) Correlation between FRAP (eq Fe(II) μM) and cognitive impairment in 
AD patients (r = 0.443, P  0.01). (B) Correlation between FRAP (eq Fe(II) μM) and 
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Figure 3 (A) Correlation between total cholesterol (mg/dL) and GDS in AD patients 
(r = −0.298, P  0.05). (B) Correlation between VLDL (mg/dL) and GDS in AD patients 
( r = −0.382, P  0.01).
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Figure 4 Correlations between Cholesterol/HDL index and Boston Naming Test 
(BNT) values in AD patients ( r = 0.464, P  0.01). Other experimental details in 
Methods section.
of AD. We found that cognitive impairment parameters 
MMSE and PRAXIAS were both positively correlated with 
the FRAP, this results indicates that oxidative damage in 
demented patientes can be promoted in part by a reduced 
ability of plasma to scavenge free radicals. Interestingly, 
in a previous report it has been suggested that a decrease in 
TAC of plasma is negatively correlated with the duration of 
moderate/severe AD and mild AD, and signiﬁ  cant increases 
in plasma total homocysteine are also present in AD patients 
(tHcy) (Guidi et al 2006).
Previous studies on the links between plasma levels of 
lipids and cholesterol with AD exihibit a marked contro-
versy. When we explored the association of plasma lipids to 
cognitive impairment in these groups we found no signiﬁ  -
cant differences in LDL, HDL, VLDL and total cholesterol 
levels between AD patients and healthy controls. This is 
consistent with recent reports decribing no association 
between lipids and the risk of amnesiac or nonamnesiac 
mild AD (Reitz et al 2008). However, we found a slightly 
negative correlation between GDS against total cholesterol, 
also GDS status against VLDL levels in AD group respect 
to controls. These clinical data may seem controversial, 
in the light of the current hypothesis that links cholesterol 
levels with amyloid pathology and tau hyperphosphoryla-
tion based on in vitro studies (Rojo et al 2006), but they are 
consistent with recent reports describing the lipid proﬁ  le of 
demented patients (Dimopoulos et al 2007) . An important 
contribution of our work to elucidate the association of 
lipids with cognitive impairment is the ﬁ  nding of a posi-
tive correlation between the cholesterol/HDL ratio and the 
impairment of semantic memory (BNT test) (Figure 4). This 
is a very interesting ﬁ  nding in the light of recent reports 
decribing correlations between metabolic syndrome and 
high risk of cognitive decline (Komulainen et al 2007; 
Panza et al 2007).
Studies of the changes in cholesterol levels have shown 
that thotal cholesterol tends to increase with age in young 
or middle-aged adults but later decreases as individuals 
get older (Abbott et al 1997; Ferrara et al 1997). Another 
study shows that total cholesterol levels in plasma were 
lower in patients with AD than in controls at least ﬁ  ve 
years before diagnosis (Mielke et al 2005), and decreased 
more rapidly among people who subsequently developed 
dementia (Notkola et al 1998). Solomon and colleagues 
(2007) have proposed that high midlife serum TC is a risk 
factor for subsequent dementia/AD, but decreasing serum 
total cholesterol after midlife may reﬂ  ect ongoing disease 
processes and may represent a risk marker for late-life cog-
nitive impairment. Apparently, several years before clinical 
evidence of dementia, total cholesterol begins to decline, 
possibly as a results of the ongoing AD pathology (Panza 
et al 2007). On the other hand, the decrease in plasma total Neuropsychiatric Disease and Treatment 2008:4(4) 721
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cholesterol in the development of disease may be partially 
explained by the physiological aging process. However, no 
correlation was evidenced between age and the total cho-
lesterol, VLD-cholesterol and cholesterol/HDL index in the 
AD patients under our study. The minor decrease detected 
with the time progression of AD might be explained by 
unintentional or voluntary changes in lifestyle-related factors 
because of the reduced quality-of-life of AD patients.
In summary, in a study on human subjects we corrobo-
rated the ﬁ  ndings that the degree of oxidative stress is directly 
related to the advance of cognitive impairment and AD. Thus, 
high correlations between the oxidative stress marker FRAP 
and cognitive impairment indicate that oxidative stress should 
be considered a risk factor in the development of cognitive 
disorders (Perry et al 2000). Oxidative stress is critical in the 
pathogenesis of AD, and is involved in biological damage, 
thus one might think that the administration of antioxidants 
may be useful in the prevention and treatment of AD and 
other neurodegenerative disorders.
In the meantime, we demonstrated that plasmatic levels of 
cholesterol also decrease with the progression of dementia in 
the AD population as evaluated by changes in GDS measure-
ments (Figure 3). This might be a result of the pathologic 
processes leading to dementia, at least during the early stages 
of the disease. The negative correlations between cholesterol 
parameters and the cognitive impairment open new questions 
about the role of cholesterol and oxidative markers in AD 
progression. Interestingly, in a recent study on the levels of 
brain redox-iron overload, a positive correlation between 
cerebral spinal ﬂ  uid redox-iron and AD progression was 
evidenced at the early stages of the disease (mild AD cases), 
but this particular iron compartment decreased at advanced 
stages of the disease (Lavados et al 2008).
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